vs
Side-by-side financial comparison of BRC Group Holdings, Inc. (RILY) and Twist Bioscience Corp (TWST). Click either name above to swap in a different company.
BRC Group Holdings, Inc. is the larger business by last-quarter revenue ($188.3M vs $103.7M, roughly 1.8× Twist Bioscience Corp). BRC Group Holdings, Inc. runs the higher net margin — 47.9% vs -29.4%, a 77.4% gap on every dollar of revenue. On growth, Twist Bioscience Corp posted the faster year-over-year revenue change (16.9% vs -21.9%).
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
RILY vs TWST — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $188.3M | $103.7M |
| Net Profit | $90.3M | $-30.5M |
| Gross Margin | 79.5% | 52.0% |
| Operating Margin | 32.3% | -31.7% |
| Net Margin | 47.9% | -29.4% |
| Revenue YoY | -21.9% | 16.9% |
| Net Profit YoY | 1710.8% | 3.4% |
| EPS (diluted) | $2.78 | $-0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $188.3M | $103.7M | ||
| Q3 25 | $215.3M | — | ||
| Q2 25 | $188.2M | — | ||
| Q1 25 | $197.2M | — | ||
| Q4 24 | $241.0M | — | ||
| Q3 24 | $225.5M | — | ||
| Q2 24 | $256.0M | — | ||
| Q1 24 | $263.4M | — |
| Q4 25 | $90.3M | $-30.5M | ||
| Q3 25 | $91.1M | — | ||
| Q2 25 | $139.5M | — | ||
| Q1 25 | $-10.0M | — | ||
| Q4 24 | $-5.6M | — | ||
| Q3 24 | $-284.4M | — | ||
| Q2 24 | $-433.6M | — | ||
| Q1 24 | $-49.2M | — |
| Q4 25 | 79.5% | 52.0% | ||
| Q3 25 | 83.7% | — | ||
| Q2 25 | 81.3% | — | ||
| Q1 25 | 81.4% | — | ||
| Q4 24 | 79.8% | — | ||
| Q3 24 | 82.1% | — | ||
| Q2 24 | 84.5% | — | ||
| Q1 24 | 85.3% | — |
| Q4 25 | 32.3% | -31.7% | ||
| Q3 25 | 30.4% | — | ||
| Q2 25 | 5.7% | — | ||
| Q1 25 | -31.2% | — | ||
| Q4 24 | -69.2% | — | ||
| Q3 24 | -36.4% | — | ||
| Q2 24 | -90.8% | — | ||
| Q1 24 | -6.1% | — |
| Q4 25 | 47.9% | -29.4% | ||
| Q3 25 | 42.3% | — | ||
| Q2 25 | 74.1% | — | ||
| Q1 25 | -5.1% | — | ||
| Q4 24 | -2.3% | — | ||
| Q3 24 | -126.1% | — | ||
| Q2 24 | -169.4% | — | ||
| Q1 24 | -18.7% | — |
| Q4 25 | $2.78 | $-0.50 | ||
| Q3 25 | $2.91 | — | ||
| Q2 25 | $4.50 | — | ||
| Q1 25 | $-0.39 | — | ||
| Q4 24 | $-0.01 | — | ||
| Q3 24 | $-9.39 | — | ||
| Q2 24 | $-14.35 | — | ||
| Q1 24 | $-1.71 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $226.6M | $197.9M |
| Total DebtLower is stronger | $1.4B | — |
| Stockholders' EquityBook value | $-171.5M | $456.1M |
| Total Assets | $1.7B | $638.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $226.6M | $197.9M | ||
| Q3 25 | $184.2M | — | ||
| Q2 25 | $267.4M | — | ||
| Q1 25 | $138.3M | — | ||
| Q4 24 | $146.9M | — | ||
| Q3 24 | $159.2M | — | ||
| Q2 24 | $236.9M | — | ||
| Q1 24 | $190.7M | — |
| Q4 25 | $1.4B | — | ||
| Q3 25 | $1.3B | — | ||
| Q2 25 | $1.3B | — | ||
| Q1 25 | $1.4B | — | ||
| Q4 24 | $1.5B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-171.5M | $456.1M | ||
| Q3 25 | $-260.5M | — | ||
| Q2 25 | $-351.7M | — | ||
| Q1 25 | $-496.8M | — | ||
| Q4 24 | $-488.2M | — | ||
| Q3 24 | $-497.6M | — | ||
| Q2 24 | $-218.3M | — | ||
| Q1 24 | $228.4M | — |
| Q4 25 | $1.7B | $638.1M | ||
| Q3 25 | $1.7B | — | ||
| Q2 25 | $1.5B | — | ||
| Q1 25 | $1.5B | — | ||
| Q4 24 | $1.8B | — | ||
| Q3 24 | $2.2B | — | ||
| Q2 24 | $3.2B | — | ||
| Q1 24 | $5.0B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $26.2M | $-24.8M |
| Free Cash FlowOCF − Capex | — | $-34.8M |
| FCF MarginFCF / Revenue | — | -33.5% |
| Capex IntensityCapex / Revenue | — | 9.6% |
| Cash ConversionOCF / Net Profit | 0.29× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $26.2M | $-24.8M | ||
| Q3 25 | $-60.6M | — | ||
| Q2 25 | $-25.6M | — | ||
| Q1 25 | $184.0K | — | ||
| Q4 24 | $-2.7M | — | ||
| Q3 24 | $19.5M | — | ||
| Q2 24 | $111.5M | — | ||
| Q1 24 | $135.4M | — |
| Q4 25 | — | $-34.8M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -33.5% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 9.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 0.29× | — | ||
| Q3 25 | -0.66× | — | ||
| Q2 25 | -0.18× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
TWST
| Industrial Chemicals | $37.2M | 36% |
| Diagnostics | $35.3M | 34% |
| Food Or Agriculture | $12.8M | 12% |
| Academic Research | $12.2M | 12% |
| Health Care | $6.1M | 6% |
